AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company aiming to become the global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and neuro-orphan indications driven by misfolded proteins. The company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, drive its broad and diversified pipeline of first-in-class and best-in-class assets, which currently includes 9 therapeutic candidates and 3 diagnostic candidates, with 6 currently in clinical trials. AC Immune has established strong strategic partnerships with leading global pharmaceutical companies, including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc.